- Home
- / Greenyn Biotechnology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Greenyn Biotechnology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
NT$78.5
2024-10-29
Market Capitalization
NT$2.1 B
2024-10-28
Revenue
NT$915.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 693.8M | 705.3M | 800.5M | 873.2M | 915.3M |
| Cost of goods sold | 312.5M | 309.2M | 383.1M | 427.4M | 439.8M |
| Gross profit | 381.9M | 398.9M | 418.8M | 447.5M | 477.8M |
| Gross profit margin, % | 55.0% | 56.6% | 52.3% | 51.2% | 52.2% |
| Operating expense total | 188.9M | 204.2M | 231.6M | 247.4M | 251.4M |
| Depreciation and amortization | 23.3M | 25.1M | 24.9M | 30.6M | 35.4M |
| EBITDA | 193.0M | 194.7M | 187.2M | 200.1M | 226.4M |
| EBITDA margin, % | 27.8% | 27.6% | 23.4% | 22.9% | 24.7% |
| EBIT | 172.3M | 170.8M | 162.1M | 168.6M | 190.9M |
| EBIT margin, % | 24.8% | 24.2% | 20.3% | 19.3% | 20.9% |
| Interest income | 290.0K | 1.2M | 5.3M | 8.3M | 11.3M |
| Interest expense | 1.4M | 1.2M | 1.7M | 1.5M | 12.0M |
| Pre tax profit | 169.0M | 184.0M | 165.8M | 183.7M | 185.0M |
| Income tax expense | 36.2M | 37.3M | 35.2M | 37.7M | 39.4M |
| Net Income | 132.8M | 146.7M | 130.7M | 146.0M | 145.5M |